Eckert & Ziegler Bebig SA
Eckert & Ziegler SE is a German isotope technology company providing medical radioisotopes, brachytherapy seeds and devices, and radiopharmaceutical CDMO services to pharmaceutical companies, hospitals, and research institutions globally for cancer therapy, nuclear-medical imaging, and industrial radiometry.
- Company typePublic
- Founded1997
- HeadquartersSeneffe, Belgium
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Eckert & Ziegler Bebig SA does
Eckert & Ziegler SE (which merged with Belgian Eckert & Ziegler BEBIG in February 2019 and now operates under the consolidated entity Eckert & Ziegler Bebig SA) is a TecDAX-listed German isotope technology company headquartered in Berlin with over 1,000 employees globally. The company is structured around three core business areas: cancer therapy (brachytherapy seeds, applicators, and radiation therapy devices), industrial radiometry (calibration sources, Krypton-85, Nickel-63), and nuclear-medical imaging (radioisotopes and radiopharmaceuticals for PET diagnostics). It manufactures and supplies medical radioisotopes including Gallium-68, Germanium-68, Lutetium-177, Yttrium-90, and Actinium-225, along with branded products such as the GalliaPharm Ge-68/Ga-68 radionuclide generator, I-125 and Pd-103 prostate brachytherapy seeds, Ru-106 eye applicators, SagiNova brachytherapy device, and Modular-Lab PharmTracer synthesis cassettes.
The business model is a B2B enterprise motion with direct sales to pharmaceutical companies developing radiopharmaceuticals, hospitals and clinics performing nuclear medicine and brachytherapy, and academic research institutions. Revenue is generated across five streams: radioisotope sales, CDMO services for radiopharmaceutical manufacturing under GMP conditions, sales of medical devices (brachytherapy seeds and applicators), manufacturing of hot cells and equipment, and specialized logistics for radioactive materials. Pricing is custom and quote-based, reflecting regulatory complexity and specialized handling. Manufacturing operations are anchored by GMP-certified facilities in Berlin-Buch, Braunschweig, and Leese (Germany), with a 50:50 joint venture (Qi Kang Medical Technology / QKM) with DongCheng Pharma operating a 9,500 m² production facility in Jintan, China.
The company converted its legal form to SE in 2024, completed a stock split in 2025, and spun off Pentixapharm AG in October 2024 to separate radiopharmaceutical drug development. Customer relationships span leading radiopharmaceutical developers including Telix Pharmaceuticals, SK Biopharmaceuticals, Actinium Pharmaceuticals, Sirtex Medical, Full-Life Technologies, POINT Biopharma, Ariceum, Bicycle Therapeutics, and Molecular Partners. Regulatory approvals span the EU, US (FDA), Japan, Canada, and Brazil, with MDR certification for prostate seeds and eye tumor treatment securing continued European market access.
Eckert & Ziegler Bebig SA firmographics
Firmographics- Name
- Eckert & Ziegler Bebig SA
- Legal name
- Eckert & Ziegler SE
- Website
- https://ezag.com
- Company type
- Public
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Eckert & Ziegler SE is a German isotope technology company providing medical radioisotopes, brachytherapy seeds and devices, and radiopharmaceutical CDMO services to pharmaceutical companies, hospitals, and research institutions globally for cancer therapy, nuclear-medical imaging, and industrial radiometry.
- Ownership category
- akta.pro rank
Eckert & Ziegler Bebig SA industry classification
Industry- Product category
- Radiopharmaceuticals and Medical Isotopes
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Medical Equipment and Supplies Manufacturing (3391), Irradiation Apparatus Manufacturing (334517)
- SIC
- Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.) (EUAKAIAA)
- akta.pro secondary industries
- Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC) (EUAKAIAC), Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology) (EUAKAIAD), Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF)
Keywords
Where Eckert & Ziegler Bebig SA is headquartered
LocationHeadquarters
- HQ city
- Seneffe
- HQ country
- Belgium
- HQ region
- Europe
Offices5 records
Markets served
Eckert & Ziegler Bebig SA business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Others
Revenue model
- Radioisotope Sales: Sale of medical radioisotopes including Gallium-68, Lutetium-177, Yttrium-90, Actinium-225, Germanium-68 to pharmaceutical companies and research institutions worldwide.
- CDMO Services: Contract development and manufacturing services for radiopharmaceuticals. GMP-certified production for clinical trials and commercial supply.
- Medical Devices: Sale of brachytherapy seeds (I-125, Pd-103), applicators, and radiation sources for cancer treatment.
- Equipment Manufacturing: Hot cells and manufacturing equipment for radiopharmaceutical production facilities.
- Radiopharmaceutical Logistics: Specialized logistics services for radioactive materials including global distribution.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Eckert & Ziegler Bebig SA product offering
Product offeringCore offering
Eckert & Ziegler SE manufactures and supplies medical radioisotopes (Gallium-68, Lutetium-177, Yttrium-90, Actinium-225, Germanium-68), brachytherapy products (I-125 and Pd-103 prostate seeds, I-125 ophthalmic seeds, Ru-106 eye applicators), the GalliaPharm Ge-68/Ga-68 radionuclide generator, the Modular-Lab PharmTracer synthesis device, and the SagiNova brachytherapy device. The group also provides contract development and manufacturing (CDMO) services for radiopharmaceuticals under GMP conditions. Customers are pharmaceutical companies, hospitals, clinics, and academic research institutions worldwide.
Product overview
Eckert & Ziegler Bebig SA operates as part of the Eckert & Ziegler Group, one of the world's largest providers of isotope technology for medical, scientific, and industrial use. The company offers a comprehensive portfolio of products and services organized across two main segments: Medical and Isotope Products. Core offerings include brachytherapy solutions (prostate seeds, eye seeds, applicators), radiopharmaceutical products (GalliaPharm® Ge-68/Ga-68 generators, therapeutic isotopes like Lutetium-177, Actinium-225, Yttrium-90), synthesis equipment (Modular-Lab PharmTracer), and CDMO contract manufacturing services. The company serves cancer therapy, nuclear-medical imaging, and industrial radiometry markets globally.
Differentiator
Problem solved
Functional benefit
Brands
- GalliaPharm: Ge-68/Ga-68 radionuclide generator for PET diagnostics
- Modular-Lab PharmTracer
- SagiNova
Products and services
- GalliaPharm Ge-68/Ga-68 Radionuclide Generator
Quantifiable outcome
- Global radioisotope supplier to leading pharmaceutical companies
- +1 more outcomes
Companies that use Eckert & Ziegler Bebig SA
Customer profileNamed customers9 records
Segments4 records
Ideal customer profiles4 records
Eckert & Ziegler Bebig SA technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Eckert & Ziegler Bebig SA partnerships and signals
Strategic signalPartnerships
20 partnerships are on record, tiered core and major.
- DongCheng Pharma (DC Pharma)coreJoint venture Qi Kang Medical Technology (QKM) for medical isotope production in China. 50:50 partnership. Production facility in Jintan, Changzhou with 9,500 m². Producing Germanium-68 initially, Actinium-225 planned for Phase 2.
- UJF (Czech Research Center)coreJoint development of Actinium-225 production. Opened high-tech Ac-225 production facility in June 2024. Significantly increased Ac-225 production volume in February 2026.
- Thor MedicalmajorPartnership announced for radiopharmaceutical development and production.
- Molecular PartnersmajorCooperation for development of radiopharmaceutical products.
- SK BiopharmaceuticalsmajorSupply contract for Actinium-225 (Ac-225) for Korean pharmaceutical company's radiopharmaceutical pipeline.
- ArcheusmajorUS manufacturing partner for Archeus' next-generation radiopharmaceutical.
- PentixapharmmajorManufacturing agreement for Yttrium-90-based PentixaTher radiopharmaceutical.
- Actinium PharmaceuticalscoreMajor Ac-225 supply for Actinium Pharmaceuticals' comprehensive clinical development program.
- AtomVie Global RadiopharmamajorWorldwide agreement for radiopharmaceutical services.
- Bicycle TherapeuticsmajorStrategic partnership for radiopharmaceutical manufacturing and development.
- Ariceum TherapeuticsmajorGlobal supply contract for Actinium-225.
- Telix PharmaceuticalscoreCooperation and license agreement. Illuccix PSMA-PET diagnostic received German approval June 2025.
- Full-Life TechnologiesmajorActinium-225 supply contract.
- ARTBIOmajorPartnership for manufacturing and development of radiopharmaceutical products.
- Ablaze PharmaceuticalsmajorSupply of Lutetium-177 for clinical trials.
- PharmaLogicmajorReservation agreement for supply of radioisotopes.
- POINT BiopharmamajorSupply of Actinium-225.
- Alpha-9majorReservation agreement for Actinium-225.
- NorthStar Medical RadioisotopesmajorBuilding Actinium-225 production line for NorthStar.
- PRECIRIXmajorPriority supply agreement for radiopharmaceutical development.
Scale indicators6 records
Recent moves12 records
Expansion highlights6 records
Eckert & Ziegler Bebig SA competitors and assessment
Company assessmentDirect peers
- Curium: One of the world's largest nuclear medicine companies producing SPECT/PET diagnostic isotopes and therapeutic radiopharmaceuticals. Directly comparable to EZAG in the radiopharmaceutical manufacturing and isotope supply business.
- NorthStar Medical Radioisotopes: US-based producer of medical radioisotopes including Mo-99/Tc-99m and is building Ac-225 production capacity — a direct competitor in medical isotope production where EZAG is also building Ac-225 capacity.
- Cardinal Health (Nuclear Pharmacy Services): Operates the largest radiopharmaceutical distribution network in the US, supplying unit-dose radiopharmaceuticals to hospitals. Directly comparable in the radiopharmacy logistics and distribution layer of EZAG's business.
- ITM Isotope Technologies Munich SE: Specialist in medical radioisotopes (notably Lu-177 / no-carrier-added) and radiopharmaceutical manufacturing with a global production network. A direct competitor in the medical isotope and CDMO market.
- PETNET Solutions (Siemens Healthineers): A leading PET radiopharmacy network distributing FDG and other PET tracers in the US and UK. Directly comparable in the PET tracer distribution/CDMO layer overlapping with EZAG's imaging tracer business.
Broad incumbents
- Bracco Imaging: Global imaging diagnostic company with a growing radiopharmaceutical portfolio. Broad incumbent in the diagnostic imaging and nuclear medicine space overlapping with EZAG's imaging tracer business.
- Lantheus Holdings: Leading radiopharmaceutical-focused company with diagnostic and therapeutic products (e.g., PYLARIFY PSMA-PET, Point Biologics acquired from POINT). Comparable to EZAG in radiopharmaceutical development, manufacturing, and commercialization.
- Siemens Healthineers (PET/Nuclear Medicine): Major medical technology company with a strong PET imaging and radiopharmacy equipment/services business. Comparable in the nuclear medicine imaging and isotope ecosystem where EZAG's Ga-68 generators and synthesis modules are used.
- Bayer (Radiology / Curium stake): Through its prior ownership of Curium and its radiology business, Bayer is a broad incumbent in radiopharmaceuticals and imaging. Comparable in the broader radiopharma industry context, including theranostics.
Emerging players
- Telix Pharmaceuticals: Radiopharmaceutical company developing diagnostic and therapeutic products (Illuccix PSMA-PET), with which EZAG has a cooperation and license agreement. Comparable as a customer/partner and as a developer of products using EZAG-supplied isotopes.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Eckert & Ziegler Bebig SA social profiles
Digital presenceEckert & Ziegler Bebig SA financial estimates
Financial estimateRevenue estimate
Valuation estimate
Eckert & Ziegler Bebig SA leadership team
Management profileNumber of profiles
Profiles2 records
Eckert & Ziegler Bebig SA subsidiaries and ownership
Company hierarchySubsidiaries2 records
Eckert & Ziegler Bebig SA funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Eckert & Ziegler Bebig SA M&A and investment
M&A and investmentM&A7 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Eckert & Ziegler Bebig SA
What does Eckert & Ziegler Bebig SA do?
Eckert & Ziegler SE manufactures and supplies medical radioisotopes (Gallium-68, Lutetium-177, Yttrium-90, Actinium-225, Germanium-68), brachytherapy products (I-125 and Pd-103 prostate seeds, I-125 ophthalmic seeds, Ru-106 eye applicators), the GalliaPharm Ge-68/Ga-68 radionuclide generator, the Modular-Lab PharmTracer synthesis device, and the SagiNova brachytherapy device. The group also provides contract development and manufacturing (CDMO) services for radiopharmaceuticals under GMP conditions. Customers are pharmaceutical companies, hospitals, clinics, and academic research institutions worldwide.
Is Eckert & Ziegler Bebig SA a public or private company?
Eckert & Ziegler Bebig SA is a public company. It is classified as public and is currently operating.
When was Eckert & Ziegler Bebig SA founded?
Eckert & Ziegler Bebig SA was founded in 1997. It employs 1,001 to 5,000 people.
Where is Eckert & Ziegler Bebig SA based?
Eckert & Ziegler Bebig SA is headquartered in Seneffe, Belgium, in the Europe region.
How does Eckert & Ziegler Bebig SA make money?
Five revenue lines are on record. Radioisotope Sales are the primary driver. The others are CDMO Services, medical Devices, equipment Manufacturing and radiopharmaceutical Logistics.
Who are Eckert & Ziegler Bebig SA's main competitors?
Direct peers on record are Curium, NorthStar Medical Radioisotopes, Cardinal Health (Nuclear Pharmacy Services), ITM Isotope Technologies Munich SE and PETNET Solutions (Siemens Healthineers). Broad incumbents are Bracco Imaging, Lantheus Holdings, Siemens Healthineers (PET/Nuclear Medicine) and Bayer (Radiology / Curium stake). Telix Pharmaceuticals is listed as an emerging player.
Does Eckert & Ziegler Bebig SA have an API?
No public API is recorded for Eckert & Ziegler Bebig SA.
What industry is Eckert & Ziegler Bebig SA in?
Eckert & Ziegler Bebig SA's product category is Radiopharmaceuticals and Medical Isotopes. Its primary akta.pro industry code is EUAKAIAA, Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.), with a secondary code of EUAKAIAC, Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC). Its NAICS code is 3254 and its SIC code is 2834.